

CONFIDENTIAL MATERIAL – SUBJECT TO PROTECTIVE ORDER

Exhibit 2005

relativity-b.kldiscovery.com/Relativity/RelativityInternal.aspx?AppID=12810289&Mode=ReviewInterface&DocumentID=3471869&ArtifactTypeID=10&ViewerTy

< Exit viewer Documents 6239292_02449774 ▾

Documents					Native Image Extracted Text ▾	
Relativity ID	BegAttach (Family ID)	Custodian	Master Date	File Name		
6239292_02449774	6239292_02449774	Yancopoulos, George	3/22/2007	TOp Line sum for PR.msg	73%	Date: Thursday, March 22 2007 06:13 PM Subject: TOp Line sum for PR From: George Yancopoulos To: Murray Goldberg <Murray.Goldberg@regeneron.com>; Attachments: Eye Ph2 Data_032207.doc
6239292_02449775	6239292_02449774	Yancopoulos, George	3/22/2007	Eye Ph2 Data_032207.doc		

CONFIDENTIAL

Exhibit 2006

relativity-b.kldiscovery.com/Relativity/RelativityInternal.aspx?AppID=12810289&Mode=ReviewInterface&DocumentID=3471870&ArtifactTypeID=10&V

Documents 6239292_02449775

Relativity ID	BegAttach (Family ID)	Custodian	Master Date	File Name
6239292_02449774	6239292_02449774	Yancopoulos, George	3/22/2007	T0p Line sum for PR.msg
6239292_02449775	6239292_02449774	Yancopoulos, George	3/22/2007	Eye Ph2 Data_032207.doc

Native Image Extracted Text RGN-EYLEA-

73%

March 22, 2007

Interim Analysis of Phase 2 Study of VEGF Trap in AMD patients

Patients treated with 5 different dosing regimens, and compared to their baseline at three months, using change in retinal thickness at three months as the key secondary endpoint

Patients treated with 0.5 mg, 2.0 mg and 4.0 mg doses, with cohorts in which patients were once with these doses and evaluated over the ensuing three months. The 0.5 and 2.0 doses were given monthly

Study achieved its pre-specified primary endpoint, of decrease in retinal thickness (all cohorts combined) at 12 weeks, with $p < 0.0001$

>>> The average decrease in retinal thickness across all five cohorts was 2.8 micrometers at 12 weeks

Study also achieved key pre-specified secondary endpoint, of improvement in visual acuity (all cohorts combined) at 12 weeks, with $p < 0.0001$

>>> The average increase in visual acuity across all five cohorts was 5.9 letters at 8 weeks, and 5.9 letters at 12 weeks

Statistical analyses did not show significant differences across the treatment groups in retinal thickness or visual acuity, regardless of whether patients received monthly or single dose or received monthly treatments

>>> The improvements in visual acuity in the different cohorts were statistically significant

Patients treated with a single dose, at all three dose levels, maintained a mean gain in visual acuity (2.8 to 5.1 letters), at 12 weeks

Only a single patient in the entire study did not at least maintain their vision at 12 weeks

Quote:

"In this 12 week study, the VEGF Trap caused statistically significant improvement in retinal thickness and visual acuity. Moreover, the VEGF Trap may prove unique in that it may have a beneficial effect on retinal swelling, as well as improve visual acuity, and may be a forward to the required Phase 3 studies to define the doses and intervals and most desirable treatment options for patients."

Key Background Comparisons to Lucentis:

Average Approximate decrease in retinal thickness (micrometers) at 12 weeks in Lucentis pivotal studies

Loss of about 2.5 letters

Mean change in VA at 1m, 3m and 1 year in Lucentis pivotal studies:

	1m	3m	12m
Marina (2m ETRDS)	0.3	-3.5	5.1
Anchor	0.5	-4	5.9
Anchor	0.3	5.9	6.8
Anchor			8.5

CONFIDENTIAL

CONFIDENTIAL MATERIAL – SUBJECT TO PROTECTIVE ORDER

Exhibit 2010

relativity-b.kldiscovery.com/Relativity/RelativityInternal.aspx?AppID=12810289&Mode=ReviewInterface&DocumentID=3303682&ArtifactTypeID=10

Documents 6239292_02293467

Relativity ID	BegAttach (Family ID)	Custodian	Master Date	File Name
6239292_02293467	6239292_02293467	Yancopoulos, George	11/19/2010	FW: Here you go.msg
6239292_02293468	6239292_02293467	Yancopoulos, George	11/19/2010	VGTEye VIEW 430 presentation.PPT

Native Image Extracted Text RGN-EYLEA-MYLAN

73%

Date: Friday, November 19 2010 09:26 PM
Subject: FW: Here you go
From: Robert Terifay
To: George Yancopoulos <George.Yancopoulos@regeneron.com>;
Attachments: VGTeye VIEW 430 presentation.PPT

From: Robert Terifay
Sent: Friday, November 19, 2010 3:53 PM
To: Alyson Berliner; Robert Vitti
Subject: Here you go

CONFIDENTIAL RGN

CONFIDENTIAL MATERIAL – SUBJECT TO PROTECTIVE ORDER

Exhibit 2011

relativity-b.kldiscovery.com/Relativity/RelativityInternal.aspx?AppID=12810289&Mode=ReviewInterface&DocumentID=3303683&ArtifactTypeID=10&ViewerType=production

Documents 6239292_02293468

Relativity ID	BegAttach (Family ID)	Custodian	Master Date	File Name
6239292_02293467	6239292_02293467	Yancopoulos, George	11/19/2010	FW: Here you go.msg
6239292_02293468	6239292_02293467	Yancopoulos, George	11/19/2010	VGTeYe VIEW 430 presentation.PPT

Native Image Extracted Text RGN-EYLEA-MYLAN_002

88%

Vascular Endothelial Growth Factor (VEGF) Trap-E
Investigation of Efficacy and Safety in
Related Macular Degeneration (A

VIEW 1 and VIEW

1-Year Results
Internal Employees

CONFIDENTIAL

CONFIDENTIAL MATERIAL – SUBJECT TO PROTECTIVE ORDER

Exhibit 2013

relativity-b.kldiscovery.com/Relativity/RelativityInternal.aspx?AppID=12810289&Mode=ReviewInterface&DocumentID=3491510&ArtifactTypeID=10

< Exit viewer Documents 6239292_02459724

Relativity ID	BegAttach (Family ID)	Custodian	Master Date	File Name
6239292_02459723	6239292_02459723	Yancopoulos, George	5/20/2008	VTeye CSC_DME_Phase2_5-19-08 - For your review and approval.msg
6239292_02459724	6239292_02459723	Yancopoulos, George	5/20/2008	CSC_DME_Phase2_5-19-08.doc

Native Image Extracted Text

69%

RE

CONFIDENTIAL

CONFIDENTIAL

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.